# Belkin Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/belkin-vision

- Industry: Medical Devices & Equipment
- Headquarters: Yavne, Israel
- Website: www.belkin-vision.com
- Total disclosed funding: $17M
- Latest round: Series B (Jul 20, 2020)
- Investors on record: 8

## About

Founded in 2013 and based in Yavne, Israel, Belkin Vision Ltd. operates as a manufacturer of non-contact and automated glaucoma laser therapy solutions. In May 2024, Alcon Labs, Inc. agreed to fully acquire Belkin Vision Ltd. from BioLight Life Sciences Investments, C-Mer Eye Care Holdings Ltd., CR Capital, European Union, RAD BioMed, Rimonci Capital, Santen Ventures, and Zicom Group for USD 65 million in cash. As part of the transaction, a payment of USD 385 million will be based on sales-based milestones. As of 2024, the company is headed by its CEO Daria Lemann-Blumenthal.

BELKIN Vision’s product range includes the Eagle™ device, which is designed for selective laser trabeculoplasty (SLT), a common procedure for managing glaucoma. The device offers a user-friendly interface, automation, and precision, enabling ophthalmologists to deliver consistent and reproducible treatment. Currently, the Eagle™ is available for sale in the EU and the UK.

## Funding rounds

- Series B, Jul 20, 2020, $12M — CR Capital, BioLight Life Sciences Investments, Rimonci Capital, Santen Ventures, C-Mer Eye Care Holdings Ltd.
- Series A, Jun 4, 2017, $5M — European Union, Zicom Group, RAD BioMed, Rimonci Capital

## Investors

- European Union — Series A
- Zicom Group — Series A
- RAD BioMed (https://capitalatlas.ai/funds/rad-biomed) — Series A
- Rimonci Capital (https://capitalatlas.ai/funds/rimonci-capital) — Series A, Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series B
- BioLight Life Sciences Investments — Series B
- Santen Ventures (https://capitalatlas.ai/funds/santen-ventures) — Series B
- C-Mer Eye Care Holdings Ltd. — Series B